Results for tag: "Zanubrutinib"

Zanubrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) used in the treatment of certain types of leukemia. It is approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Zanubrutinib is also being studied in clinical trials for the treatment of chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia (WM). Zanubrutinib works by blocking the activity of BTK, a protein that plays a role in the survival and proliferation of B-cells, which are a type of white blood cell. By blocking BTK, zanubrutinib can help reduce the number of B-cells in the body and slow the progression of certain types of leukemia. Zanubrutinib is marketed by BeiGene, a biopharmaceutical company based in China. Other companies involved in the development and marketing of zanubrutinib include AbbVie, AstraZeneca, and Janssen Pharmaceuticals. Show Less Read more